Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293


Genetic variation in the 3'-untranslated region of PAK1 influences schizophrenia susceptibility.

Jiang J, Long J, Ling W, Huang G, Su L.

Exp Ther Med. 2017 Mar;13(3):1101-1108. doi: 10.3892/etm.2017.4039. Epub 2017 Jan 12.


Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Maksymetz J, Moran SP, Conn PJ.

Mol Brain. 2017 Apr 26;10(1):15. doi: 10.1186/s13041-017-0293-z. Review.


Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia.

Kadasah S, Arfin M, Rizvi S, Al-Asmari M, Al-Asmari A.

Neuropsychiatr Dis Treat. 2017 Apr 12;13:1081-1088. doi: 10.2147/NDT.S131144. eCollection 2017.


Improving our understanding of the in vivo modelling of psychotic disorders: A protocol for a systematic review and meta-analysis.

Bahor Z, Nunes-Fonseca C, Thomson LD, Sena ES, Macleod MR.

Evid Based Preclin Med. 2016 Dec;3(2):e00022. doi: 10.1002/ebm2.22. Epub 2017 Mar 17. Review.


Assessment of the consequences of caregiving in psychosis: a psychometric comparison of the Zarit Burden Interview (ZBI) and the Involvement Evaluation Questionnaire (IEQ).

Gonçalves-Pereira M, González-Fraile E, Santos-Zorrozúa B, Martín-Carrasco M, Fernández-Catalina P, Domínguez-Panchón AI, Muñoz-Hermoso P, Ballesteros J.

Health Qual Life Outcomes. 2017 Apr 5;15(1):63. doi: 10.1186/s12955-017-0626-8.


A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.

Kim YK, Choi J, Park SC.

Int J Mol Sci. 2017 Mar 30;18(4). pii: E734. doi: 10.3390/ijms18040734. Review.


Gender-Specific Associations between CHGB Genetic Variants and Schizophrenia in a Korean Population.

Shin JG, Kim JH, Park CS, Kim BJ, Kim JW, Choi IG, Hwang J, Shin HD, Woo SI.

Yonsei Med J. 2017 May;58(3):619-625. doi: 10.3349/ymj.2017.58.3.619.


Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.

Bodén R, Persson J, Wall A, Lubberink M, Ekselius L, Larsson EM, Antoni G.

Transl Psychiatry. 2017 Mar 7;7(3):e1050. doi: 10.1038/tp.2017.11.


Experimental evidence for circular inference in schizophrenia.

Jardri R, Duverne S, Litvinova AS, Denève S.

Nat Commun. 2017 Jan 31;8:14218. doi: 10.1038/ncomms14218.


Redox Probing for Chemical Information of Oxidative Stress.

Kim E, Winkler TE, Kitchen C, Kang M, Banis G, Bentley WE, Kelly DL, Ghodssi R, Payne GF.

Anal Chem. 2017 Feb 7;89(3):1583-1592. doi: 10.1021/acs.analchem.6b03620. Epub 2017 Jan 12.


Development of 1H-Pyrazolo[3,4-b]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.

Hill MD, Fang H, Brown JM, Molski T, Easton A, Han X, Miller R, Hill-Drzewi M, Gallagher L, Matchett M, Gulianello M, Balakrishnan A, Bertekap RL, Santone KS, Whiterock VJ, Zhuo X, Bronson JJ, Macor JE, Degnan AP.

ACS Med Chem Lett. 2016 Oct 3;7(12):1082-1086. eCollection 2016 Dec 8.


Rethinking Schizophrenia in the Context of the Person and Their Circumstances: Seven Reasons.

Pérez-Álvarez M, García-Montes JM, Vallina-Fernández O, Perona-Garcelán S.

Front Psychol. 2016 Nov 3;7:1650. eCollection 2016.


Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models.

Moran P, Stokes J, Marr J, Bock G, Desbonnet L, Waddington J, O'Tuathaigh C.

Neural Plast. 2016;2016:2173748. Epub 2016 Sep 20. Review.


Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.

Shoja Shafti S, Azizi Khoei A.

Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. Epub 2016 Sep 14.


Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia.

Huang M, Huang Y, Yu L, Hu J, Chen J, Jin P, Xu W, Wei N, Hu S, Qi H, Xu Y.

BMC Psychiatry. 2016 Oct 6;16(1):344.


The Neonatal Ventral Hippocampal Lesion (NVHL) Rodent Model of Schizophrenia.

Brady AM.

Curr Protoc Neurosci. 2016 Oct 3;77:9.55.1-9.55.17. doi: 10.1002/cpns.15.


Extent and pattern of burden of care and its associated factors among Eritrean families of persons living with schizophrenia: a cross-sectional study.

Hidru TH, Osman MH, Lolokote S, Li X.

BMJ Open. 2016 Sep 28;6(9):e012127. doi: 10.1136/bmjopen-2016-012127.


Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC.

Front Pharmacol. 2016 Sep 9;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016. Review.

Supplemental Content

Support Center